CHRS Coherus BioSciences Inc.

+0.37  (+2%)
Previous Close 18.51
Open 18.73
Price To Book -314.67
Market Cap 1,317,143,716
Shares 69,763,968
Volume 716,195
Short Ratio
Av. Daily Volume 1,102,465

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
Rheumatoid arthritis
Phase 2b data released June 2016
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due in 2020.
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
FDA approval announced November 2, 2018.
Pegfilgrastim biosimilar

Latest News

  1. Edited Transcript of CHRS earnings conference call or presentation 1-Aug-19 8:30pm GMT
  2. Coherus BioSciences, Inc. (CHRS) Q2 2019 Earnings Call Transcript
  3. Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates
  4. Coherus BioSciences Reports Corporate Highlights and Second Quarter 2019 Financial Results
  5. Steven Cohen Charges Into Chiasma
  6. Coherus BioSciences Reports Victory in Pegfilgrastim Patent Dispute
  7. Coherus BioSciences Announces New Employment Inducement Grants
  8. Top Ranked Momentum Stocks to Buy for July 12th
  9. Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today
  10. Here's Why Coherus BioSciences Is Falling Today
  11. Are Investors Undervaluing Coherus BioSciences, Inc. (NASDAQ:CHRS) By 20%?
  12. Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million
  13. Coherus BioSciences to Report Second Quarter Financial Results on August 1st
  14. Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes
  15. Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
  16. Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)
  17. See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
  18. Amgen (AMGN) Offers to Acquire Drug Discovery Platform